Each uncoated tablet contains Gliclazide IP 80 mg.

Dianorm Tablets contain Gliclazide, a second-generation sulfonylurea indicated for the management of type 2 diabetes mellitus. Gliclazide stimulates insulin secretion from functional pancreatic β-cells and also exhibits beneficial hemovascular effects by reducing platelet aggregation and improving fibrinolytic activity. These additional vascular benefits may help reduce the risk of diabetic microvascular complications. The once-daily oral formulation provides effective glycemic control and supports long-term diabetes management alongside diet and lifestyle modification.

Dianorm Tablets are indicated for the treatment of maturity-onset diabetes mellitus (type 2 diabetes mellitus) in adults, including patients with or without obesity, when adequate glycemic control cannot be achieved by diet and lifestyle measures alone.

Gliclazide is a second-generation sulfonylurea that lowers blood glucose by stimulating insulin secretion from pancreatic β-cells. In addition to its antihyperglycemic activity, Gliclazide decreases microthrombosis through two important mechanisms: partial inhibition of platelet aggregation and platelet adhesion with a reduction in platelet activation markers such as beta-thromboglobulin and thromboxane B₂, and enhancement of vascular endothelial fibrinolytic activity through increased tissue plasminogen activator (tPA) activity. These effects may contribute to reducing diabetes-related vascular complications.

The recommended dosage is one Gliclazide 80 mg tablet taken orally once daily or as directed by the treating physician. The tablet should preferably be taken with breakfast or the first main meal of the day. Dosage should be individualized according to the patient's glycemic response and overall clinical condition.

Dianorm Tablets are contraindicated in patients with severe renal impairment and in patients with known hypersensitivity to Gliclazide, other sulfonylureas, sulfonamides, or any component of the formulation.